Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Continuation of Oral ONC201 in Advanced Solid Tumors
NCT02324621Phase 1Completed
- Sponsor
- Rutgers University
- Start
- Feb 2015
- Primary completion
- Oct 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of abrocitinib in solid tumor (advanced stage), sponsored by Rutgers University. Primary endpoint: Incidence of adverse experiences from oral ONC201. Started Feb 2015; status: completed.
02
Drugs
abrocitinib
03
Conditions
solid tumor (advanced stage)
Beyond the preview
Go deeper on NCT02324621.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02324621.